AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Celcuity Soars 17.16% on New Patent for Breast Cancer Drug
Generated by AI AgentAinvest Pre-Market Radar
Monday, Jul 14, 2025 8:30 am ET1min read
On July 14, 2025, Celcuity's stock surged by 17.16% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.
Celcuity has recently secured a new U.S. patent (No. 12,350,276) for the clinical dosing regimen of gedatolisib, its lead drug candidate for ER+/HER2- breast cancer. This patent extends the company's exclusivity in the U.S. until 2042, reflecting Celcuity's commitment to enhancing its intellectual property portfolio.
The new patent is part of Celcuity's broader strategy to strengthen its position in the market. With 13 granted gedatolisib-related patents in the U.S. and 290 patents globally, the company is well-positioned to capitalize on the growing demand for innovative cancer treatments.
This development has been met with enthusiasm from investors, who see the extended patent exclusivity as a significant advantage. The patent not only protects Celcuity's lead drug candidate but also opens up new opportunities for the company to explore further advancements in cancer treatment.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet